Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM): later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM): 3 US clinical trials tracked, none currently recruiting.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Ionis Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition transthyretin-mediated-amyloid-cardiomyopathy-attr-cm
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals
NCT04136171
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
Ionis Pharmaceuticals
NCT06073574
The CARDIO-TTRansform Scintigraphy Sub-study
Ionis Pharmaceuticals
NCT06073587
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ionis Pharmaceuticals sponsors the most Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) trials on record, review their full trial history before evaluating a specific study. See Ionis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) condition card totals 3 registered trials; most-linked intervention Scintigraphy scan; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.